DCA is in clinical trials and results are expected with great interest. Meanwhile stories can be heard from people, even read on the internet, that tell us that they or their relatives have benefited from using DCA against cancer expecially when combining it with other treatments.

For instance, on the DCA site, combination of DCA with fatty acid metabolism inhibitors (such as green tea extracts and others) is suggested. The original paper of Michelakis itself would suggest that apoptosis triggering substances would be potentiated by the pro-apoptotic effect of DCA.

In addition one could think that a more pronounced starvation of cancer cells could be obtained by a combination with DCA and other glycolysis inhibitors, in particular both those that target the gatekeeping Hexokinase II or the crucial LDH-A enzymes could be very helpful.

Among the Hexokinase II inhibitors we have found substances that have been demonstrated to have strong anticancer potential in preclinical studies, such as the bromopyruvate and last generation derivatives, such as BrOP.

Among the LDH-A inhibitors we have found, for instance the oxamate, wich alone has shown preclinical anticancer efficacy against breast cancer cells and the ukrain drug, which is a well known anticancer alternative treatment available.

Results of combining similar, relatively safe substances, is at present unpredictable. Also the timing and type of such potential combinations has never been evaluated. Therefore, preclinical animal studies are strongly warranted.

However, the rational for attacking cancer cell energy supplies seems very strong and we would specualte the above substances as potential DCA enhancer for anticancer alternative therapies.